| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | PROSENSA HLDG N V SHS USD | 6,213,924 | 34,860,000 | 19.23% | ||
| 2 | Dicerna Pharmaceuticals | 1,182,196 | 33,314,000 | 18.38% | ||
| 3 | SUPERNUS PHARMACEUTICALS INC COM | 3,600,000 | 32,148,000 | 17.74% | ||
| 4 | PORTOLA PHARMACEUTICALS INC | 1,240,912 | 32,140,000 | 17.73% | ||
| 5 | AMARIN CORP PLC | 8,087,486 | 14,638,000 | 8.08% | ||
| 6 | CEMPRA INC | 714,285 | 8,243,000 | 4.55% | ||
| 7 | OncoGenex Pharmaceuticals Inc | 603,740 | 7,088,000 | 3.91% | ||
| 8 | ZOGENIX INC | 2,335,218 | 6,632,000 | 3.66% | ||
| 9 | GW PHARMACEUTICALS PLC | 102,200 | 6,067,000 | 3.35% | ||
| 10 | REGULUS THERAPEUTICS INC | 327,350 | 2,943,000 | 1.62% | ||
| 11 | HYPERION THERAPEUTICS INC | 62,500 | 1,612,000 | 0.89% | ||
| 12 | ANTHERA PHARMACEUTICALS, INC. | 437,994 | 1,467,000 | 0.81% | ||
| 13 | Zalicus Inc | 78,966 | 96,000 | 0.05% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-14-006465, filed 2014.05.21).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
